CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Overview
NASDAQ:CYCCP - US23254L2079
CYCCP Key Statistics, Chart & Performance
The current stock price of CYCCP is 5.39 USD. In the past month the price decreased by -1.86%. In the past year, price decreased by -96.13%.
CYCCP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About CYCCP
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company is headquartered in Berkeley Heights, New Jersey. The firm is focused on developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its epigenetic/anti-mitotic program is evaluating plogo, a Polo-like kinase 1 (PLK1) inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle, and is a regulator of the DNA damage checkpoint. The Company’s plogo is a novel, small-molecule, selective and potent PLK1 inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogo in solid tumor and hematological malignancy indications. PLK1 over-expressing tumors include colorectal, esophageal, gastric, leukemia, lung, lymphoma, ovarian and squamous cell cancers.
Company Info
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
200 Connell Dr Ste 1500
Berkeley Heights NEW JERSEY 07922 US
CEO: Spiro Rombotis
Employees: 12
Phone: 19085177330
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP FAQ
What is the stock price of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP today?
The current stock price of CYCCP is 5.39 USD. The price decreased by -0.55% in the last trading session.
What is the ticker symbol for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP stock?
The exchange symbol of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP is CYCCP and it is listed on the Nasdaq exchange.
On which exchange is CYCCP stock listed?
CYCCP stock is listed on the Nasdaq exchange.
What is CYCLACEL PHARMACEUTICALS - CYCC 6 PERP worth?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a market capitalization of 12.07M USD. This makes CYCCP a Nano Cap stock.
How many employees does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP have?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) currently has 12 employees.
What are the support and resistance levels for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a resistance level at 5.92. Check the full technical report for a detailed analysis of CYCCP support and resistance levels.
Is CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) expected to grow?
The Revenue of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is expected to grow by 88.68% in the next year. Check the estimates tab for more information on the CYCCP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYCCP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYCCP, evaluating the profitability, health, valuation and growth aspects
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Sales and EPS estimates to see what analysts future expectations are.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Chart to make your own analysis
- CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Latest news and press-releases to stay up to date.
Does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock pay dividends?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a dividend yield of 5.57%. The yearly dividend amount is currently 0.03. Check the full fundamental report for a detailed analysis of CYCCP dividend history, reliability and sustainability.
When does CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) report earnings?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP)?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-293.82).
CYCCP Technical Analysis
CYCCP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYCCP. While CYCCP seems to be doing ok healthwise, there are quite some concerns on its profitability.
CYCCP Financial Highlights
Over the last trailing twelve months CYCCP reported a non-GAAP Earnings per Share(EPS) of -293.82. The EPS increased by 94.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -223.54% | ||
| ROE | -272.6% | ||
| Debt/Equity | 0 |
CYCCP Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for CYCCP